Immune infiltration related CENPI associates with the malignant features and drug resistance of lung adenocarcinoma
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 2024-03 · 1870 (4) · 167017
DOI: 10.1016/j.bbadis.2024.167017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2024-03. Verfasst von Ziyang Feng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Central South University, National Key Research and Development Program of China.
Abstract (Originalsprache)
Centromere protein I (CENPI) is an important member of centromeric proteins family, which is crucial to chromosome alignment and segregation. Nevertheless, the interrelation between CENPI expression and tumor progression is in the shadows. In this reserch, we carried out a panoramic bioinformatic analysis about CENPI with TCGA, Timer 2.0, Oncomine, GEPIA, Cbioportal, LinkedOmics and CancerSEA databases. Besides, our bioinformatic results have been further confirmed through in vitro experiments, including Real-Time quantitative PCR (RT-qPCR), immunofluorescence (IF), immunohistochemistry (IHC), western blotting (WB), cell proliferation assays, EdU, cell cycle and apoptosis test. Our results suggested that CENPI was increased in most of the cancers, and may serve as a potential biomarker. What's more, the knock down of CENPI inhibited the expression of CDK2 in lung adenocarcinoma (LUAD), and resulted in the arrest of G0/G1 phase and apoptosis. Besides, CENPI was related to immune cells infiltration and drug sensitivity in pan-cancer, and can act as a potential treatment target to cure cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
- Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
- Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan 4…
- Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China. Electronic address: vccj07@csu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Central South University
- National Key Research and Development Program of China
- Key Research and Development Project of Hainan Province
- National Key Research and Development Program of China Stem Cell and Translational Research
- Cancer Research Foundation
Zitieren
APA
Feng, Z., Cui, G., Tan, J., Liu, P., Chen, Y., Jiang, Z., Han, Y., Zeng, S., Shen, H., & Cai, C. (2024). Immune infiltration related CENPI associates with the malignant features and drug resistance of lung adenocarcinoma. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1870(4), 167017. https://doi.org/10.1016/j.bbadis.2024.167017
Vancouver
Feng Z, Cui G, Tan J, Liu P, Chen Y, Jiang Z, et al. Immune infiltration related CENPI associates with the malignant features and drug resistance of lung adenocarcinoma. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2024;1870(4):167017. doi:10.1016/j.bbadis.2024.167017
BibTeX
@article{Feng2024,
author = {Feng, Ziyang and Cui, Guangzu and Tan, Jun and Liu, Ping and Chen, Yihong and Jiang, Zhaohui and Han, Ying and Zeng, Shan and Shen, Hong and Cai, Changjing},
title = {Immune infiltration related CENPI associates with the malignant features and drug resistance of lung adenocarcinoma},
journal = {Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease},
year = {2024},
volume = {1870},
number = {4},
pages = {167017},
doi = {10.1016/j.bbadis.2024.167017}
}
EUVIMED